Boston Scientific Valuation
Is B1SX34 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of B1SX34 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: B1SX34 (R$519.48) is trading above our estimate of fair value (R$345.85)
Significantly Below Fair Value: B1SX34 is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for B1SX34?
Key metric: As B1SX34 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is B1SX34's PE Ratio? | |
|---|---|
| PE Ratio | 74.3x |
| Earnings | US$1.79b |
| Market Cap | US$133.13b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 8.9x |
| Enterprise Value/EBITDA | 35x |
| PEG Ratio | 3.2x |
Price to Earnings Ratio vs Peers
How does B1SX34's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 46.9x | ||
SYK Stryker | 41.3x | 11.4% | US$148.2b |
MDT Medtronic | 25.4x | 10.1% | US$109.0b |
ISRG Intuitive Surgical | 85.6x | 11.5% | US$191.9b |
ABT Abbott Laboratories | 35.4x | 11.6% | US$203.2b |
B1SX34 Boston Scientific | 74.3x | 23.2% | R$133.1b |
Price-To-Earnings vs Peers: B1SX34 is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the peer average (46.9x).
Price to Earnings Ratio vs Industry
How does B1SX34's PE Ratio compare vs other companies in the Global Medical Equipment Industry?
| 10 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: B1SX34 is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the Global Medical Equipment industry average (27.9x).
Price to Earnings Ratio vs Fair Ratio
What is B1SX34's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 74.3x |
| Fair PE Ratio | 18.1x |
Price-To-Earnings vs Fair Ratio: B1SX34 is expensive based on its Price-To-Earnings Ratio (74.3x) compared to the estimated Fair Price-To-Earnings Ratio (18.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CVS Health
US$70.2b
Provides health solutions in the United States.
CVSH34
US$32.34
7D
4.3%
1Y
-4.7%
Centene
US$29.7b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
C1NC34
US$336.60
7D
-1.4%
1Y
-6.4%
Tandem Diabetes Care
US$1.9b
A medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally.
T2ND34
US$11.06
7D
-9.5%
1Y
n/a